Loading...
•
Sep 30, 2024
Castle Biosciences Q3 2024 Earnings Report
Revenue increased by 39% year-over-year, driven by growth in test report deliveries and expanded clinical evidence supporting their use. Achieved profitability and raised full-year revenue guidance.
Key Takeaways
Castle Biosciences reported strong Q3 2024 results, with a 39% increase in revenue compared to Q3 2023, reaching $85.8 million. The company also saw a 41% increase in total test reports delivered. As a result of this strong performance, Castle Biosciences raised its full-year 2024 revenue guidance to $320-330 million.
Q3 2024 revenue increased 39% over Q3 2023 to $86 million.
Q3 2024 total test reports increased 41% over Q3 2023.
Net income was $2.3 million, compared to a net loss of $(6.9) million for the same period in 2023.
Full-year 2024 revenue guidance was raised to $320-330 million from $275-300 million.
Forward Guidance
The Company is increasing its guidance for anticipated total revenue in 2024 to between $320-330 million, compared to the previously provided guidance of between $275-300 million.
Positive Outlook
- Raising full-year 2024 revenue guidance to $320-330 million.
- DecisionDx-SCC test provides more precise risk stratification.
- DecisionDx-Melanoma can identify patients with a low risk of sentinel lymph node positivity.
- TissueCypher Barrett’s Esophagus test to independently predict risk of progression to esophageal cancer.
- TissueCypher significantly influenced physician management decisions for patients with non-dysplastic BE.
Challenges Ahead
- Subsequent study or trial results and findings may contradict earlier study or trial results and findings.
- Planned installation of additional equipment and supporting technology infrastructures and implementation of certain process efficiencies may not enable increase the future scalability of TissueCypher Test.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...